With Roche's latest deal, a new contender enters the obesity space, which could threaten NVO and LLY's dominance in the ...

Given the optimism around its obesity candidate, we believe investors should stay invested in Viking Therapeutics.

Homegrown pharmaceutical companies launching significantly cheaper generic versions of empagliflozin—a widely prescribed SGLT2 inhibitor for type-2 diabetes ...

The Philippines is not only known for its stunning landscapes and warm-hearted people but also for its brilliant minds that ...

The Oklahoma high school basketball playoffs continue this week, with the OSSAA Class 5A state tournament quarterfinals ...